The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer

Colorectal Disease

Volumn 16, Issue 10, 2014, Pages 794-800

  Keeler, B D ^a,b   Simpson, J A ^a,b   Ng, S ^b   Tselepis, C ^c   Iqbal, T ^d   Brookes, M J ^c,e   Acheson, A G ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Cancer; Other; Surgery

Indexed keywords

C REACTIVE PROTEIN; ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; HEMOGLOBIN; TRANSFERRIN; FERRIC ION; MALTOSE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEASIBILITY STUDY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; SINGLE DRUG DOSE; TREATMENT RESPONSE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; METABOLISM; MIDDLE AGED; PILOT STUDY; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANEMIA; C-REACTIVE PROTEIN; COLORECTAL NEOPLASMS; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FEASIBILITY STUDIES; FEMALE; FERRIC COMPOUNDS; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MALTOSE; MIDDLE AGED; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; TRANSFERRINS;

EID: 84907024061     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12683     Document Type: Article

References (22)

1. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-306.
2. Leichtle SW, Mouawad NJ, Lampman R, Singal B, Cleary RK. Does preoperative anemia adversely affect colon and rectal surgery outcomes? J Am Coll Surg 2011; 212:187-94.
3. Carson JL, Duff A, Poses RM et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996; 348: 1055-60.
4. Dunne JR, Malone D, Tracy JK, Gannon C, Napolitano LM. Perioperative anemia: an independent risk factor for infection, mortality, and resource utilization in surgery. J Surg Res 2002; 102: 237-44.
5. Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg 2012; 256: 235-44.
6. Khalafallah AA, Abdul MA, Chan J et al. A prospective randomized controlled trial to assess the effect of intravenous versus oral iron therapy in the treatment of orthopaedic preoperative anaemia. J Blood Disord Transfus 2012; 3:127-33.
7. Quinn M, Drummond RJ, Ross F, Murray J, Murphy J, Macdonald A. Short course pre-operative ferrous sulphate supplementation is it worthwhile in patients with colorectal cancer? Ann R Coll Surg Engl 2010; 92: 569-72.
8. Lidder PG, Sanders G, Whitehead E et al. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery - a prospective, randomised, controlled trial. Ann R Coll Surg Engl 2007; 89: 418-21.
9. Edwards TJ, Noble EJ, Durran A, Mellor N, Hosie KB. Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. Br J Surg 2009; 96: 1122-8.
10. Zhang X, Rovin BH. Beyond anemia: hepcidin, monocytes and inflammation. Biol Chem 2013; 394: 231-8.
11. Ward DG, Roberts K, Brookes MJ et al. Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol 2008; 14: 1339-45.
12. Roberts K, Ward DG, Brookes MJ et al. Hepcidin expression relates to colorectal tumour stage. Gastroenterology 2008; 134: 447.
13. Auerbach M, Ballard H. Clinical use of intravenous iron:administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010; 2010: 338-47.
14. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva, Switzerland:World Health Organistaion, 2011.
15. Ward DG, Roberts K, Stonelake P et al. SELDI-TOF-MS determination of hepcidin in clinical samples using stable isotope labelled hepcidin as an internal standard. Proteome Sci 2008; 6: doi: 10.1186/1477-5956-6-28.
16. UKBT. United Kingdom Blood Transfusion and Tissue Transplantation Guidelines. http://www.transfusionguidelines.org.uk/index.aspx 2012 [cited 2014 February].
17. Evstatiev R, Marteau P, Iqbal T et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846-53 e2
18. Beshara S, Sorensen J, Lubberink M et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol 2003; 120: 853-9.
19. Freire WB. Hemoglobin as a predictor of response to iron therapy and its use in screening and prevalence estimates. Am J Clin Nutr 1989; 50: 1442-9.
20. Bregman DB, Morris D, Koch TA, He A, Goodnough LT. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013; 88: 97-101.
21. Cladellas M, Farre N, Comin-Colet J et al. Effects of Preoperative Intravenous Erythropoietin Plus Iron on Outcome in Anemic Patients After Cardiac Valve Replacement. Am J Cardiol 2012; 110: 1021-6.
22. Pascual M, Bohle B, Alonso S et al. Preoperative administration of erythropoietin stimulates tumor recurrence after surgical excision of colon cancer in mice by a vascular endothelial growth factor-independent mechanism. J Surg Res 2013; 183: 270-7